MacroGenics is a leader in the discovery and development of innovative medicinces that utilize the next generation antibody-based technologies. With a team of 150+ dedicated individuals advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases, the company’s products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe.

MacroGenics’ innovative product candidates leverage fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms:

  • Dual-Affinity Re-Targeting (DART™) platform enables. This technology platform allows scientists to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule;
  • The Fc Optimization platform enhances the natural immune system’s ability to mediate killing of cancer cells; and
  • The company’s Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

9640 Medical Center Drive
Rockville, MD 20850
U.S.A.

MabPlex
 

Web: MacroGenics, Inc.